Figure 2From: Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot studyNumber of lung segments with high-resolution computed tomography ground-glass opacities and honeycombing in all patients at baseline and at 6Â months. Number of lung segments with high-resolution computed tomography ground-glass opacities (A) and honeycombing (B) in all 26 patients at baseline and at 6Â months (T6), and in the subgroups of patients classified as improved, stabilized, and worsened after 6Â months of treatment with imatinib (C). (A), (B) Data expressed as median with interquartile ranges. (C) Data expressed as absolute numbers of lung segments.Back to article page